Fulcrum therapeutics announces proof-of-concept for ftx-6058 in sickle cell disease based on initial data from the ongoing phase 1b trial

- achieved up to 6.3% hemoglobin f (hbf) induction in initial subjects in first cohort; hbf was increasing at last measured timepoint
FULC Ratings Summary
FULC Quant Ranking